Last reviewed · How we verify
Uroselective alpha-1-adrenergic receptor antagonist
The uroselective alpha-1-adrenergic receptor antagonist, developed by Mayo Clinic, is currently marketed but lacks detailed revenue figures and primary indication data. A key strength is the protection offered by the key composition patent, which expires in 2028. The primary risk is the lack of clear competitive positioning and trial results, which may impact market adoption and reimbursement.
At a glance
| Generic name | Uroselective alpha-1-adrenergic receptor antagonist |
|---|---|
| Also known as | Tamsulosin |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: